Résumés
Résumé
L’intérêt pour la psilocybine, une substance présente dans les champignons dits « magiques », connaît un regain marqué en psychiatrie et en soins palliatifs. Bien étudiée dans les années 1950 et 1960, elle est tombée dans l’oubli avec l’interdiction des drogues et le déclin de la contre-culture dans les années 1970. Aujourd’hui, son retour soulève des questions sur son potentiel en soins palliatifs, les bénéficiaires possibles et les modalités d’accès pour les patients, suscitant ainsi une réflexion sur les implications de son utilisation dans le contexte contemporain des soins palliatifs.
Mots-clés :
- Soins palliatifs,
- Psilocybine,
- Détresse existentielle,
- Thérapie psychédélique,
- Psychothérapie,
- Pratique innovante
Abstract
There is currently a growing interest in the use of psilocybin, a substance found in magic mushrooms, in psychiatry and palliative care, although this molecule is not new. Well studied in the 1950s and 1960s, the potential of psilocybin was explored but forgotten with the drug bans and the decline of counterculture in the 1970s. As interest in this substance is revived, questions arise about its potential in palliative care, potential beneficiaries, and access modalities for patients, thus prompting reflection on the implications of its use in the contemporary context of palliative care.
Keywords:
- Palliative care,
- psilocybin,
- existential distress,
- psychedelix therapy,
- psychotherapy,
- innovative practice
Parties annexes
Bibliographie
- Agrawal, M., Richards, W., Beaussant, Y., Shnayder, S., Ameli, R., Roddy, K., Stevens, N., Richards, B., Schor, N., Honstein, H. et al. (2024). Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder. Cancer. 130(7), 1137-1146. https://doi.org/10.1002/cncr.35010
- Barrett, F., Johnson, M., Griffiths, R. (2016). Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. Journal of Psychopharmacoly. 29(11), 258-269. https://doi.org/10.1177/0269881115609019
- Bauereiß, N., Obermaier, S., Özünal, S.E., Harald, B. (2018). Effects of existential interventions on spiritual, psychological, and physical well-being in adult patients with cancer: Systematic review and meta-analysis of randomized controlled trials. Psycho-Oncology. 27(11), 2531-2545. https://doi.org/10.1002/pon.4829
- Griffiths, R., Johnson, M., Carducci, M., Umbricht, A., Richards, W., Richards, B., Cosimano, M., Klinedinst, M. (2016) Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacoly. 30(12), 1181-1197. https://doi.org/10.1177/0269881116675513
- Grob, C., Danforth, A., Chopra, G., Hagerty, M., McKay, C., Halberstadt, A., Greer, G. (2011). Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Archives of General Psychiatry. 68(1), 71-8. https://doi.org/10.1001/archgenpsychiatry.2010.116
- Chochinov HM. (2006). Dying, dignity, and new horizons in palliative end-of-life care. CA Cancer Journal for Clinicians. 56(2), 84-103. https://doi.org/10.3322/canjclin.56.2.84
- Lewis, B., Garland, E., Byrne, K., Durns, T., Hendrick, J., Beck, A., Thielking, P. (2023). HOPE: A Pilot Study of Psilocybin Enhanced Group Psychotherapy in Patients with Cancer. Journal of Pain Symptom Management. 66(3), 258-269. https://doi.org/10.1016/j.jpainsymman.2023.06.006
- MacCallum, C., Lo, L., Pistawka, C., Deol, J. (2022). Therapeutic use of psilocybin: Practical considerations for dosing and administration. Front Psychiatry. 13: 1040217. https://doi.org/10.3389/fpsyt.2022.1040217
- Mitchell, A., Chan, M., Bhatti, H., Halton, M., Grassi, L., Johansen C., Meader, N. (2011). Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. The Lancet Oncology. 12(2), 160-74. https://doi.org/10.1016/S1470-2045(11)70002-X
- Parchett-Marble, R., O’Sullivan, S., Tadwalkar, S., Hapke, E. (2022). Psilocybin mushrooms for psychological and existential distress. Canadian Family Physician. 68(11), 823-827. https://doi.org/10.46747/cfp.6811823
- Pollan, M. (2018). How to Change Your Mind: What the New Science of Psychedelics Teaches Us About Consciousness, Dying, Addiction, Depression, and Transcendence, Penguin Press, New York.
- Ross, S., Agin-Liebes, G., Lo, S., Zeifman, R., Ghazal, L., Benville, J., Corso, S., Real, C., Guss, J., Mennenga, S. et al. (2021). Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer. ACS Pharmacology & Translational Science Journal, 18, 4(2), 1165-1180. https://doi.org/10.1021/acsptsci.1c00020
- Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Menenga, S., Belser, A., Kalliontzi, K., Schmidt, B. et al. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of Psychopharmacoly. 30(12), 1165-1180. https://doi.org/10.1177/0269881116675512
- Yaden, D., Nayak, S., Gukasyan, N., Anderson, B., Griffiths, R. (2022). The Potential of Psychedelics for End of Life and Palliative Care. Current Topics in Behavioral Neurosciences. 56: 169-184. https://doi.org/10.1007/7854_2021_278